The company has developed two vaccines, ChiVax and ChiVax-gD, which are highly effective in inducing potent and sustained T cell-mediated immune responses against transformed or infected cells. These vaccines have completed pre-clinical testing and are ready for translation into clinical trials for multiple indications. With their scientific and management expertise, Virion Therapeutics aims to address unmet medical needs by potentially curing diseases like HPV-induced cancers and chronic Hepatitis B infections. Headquartered in Newark, Delaware, the company is focused on developing novel immunotherapies that combine checkpoint blockade with disease-specific antigenic stimulation to prevent tumor or viral escape.